CClinicalTrials.gg
Status unknownNCT05062967Updated Sep 30, 2021

Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease

An observational study in Hepatitis, Liver Diseases and Acute Hepatitis, sponsored by Maimónides Biomedical Research Institute of Córdoba. Status unknown at 10 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-30.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Observational

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
3,257
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this study is to evaluate the prevalence and the clinical impact of Orthohepevirus C infection in different human populations, and to determine its zoonotic origin comparing the sequences obtained in both human and animal populations. This is an ambispective study where Orthohepevirus C infection will be evaluated in four high risk human population: i) patients with acute hepatitis, ii) patients with positive IgM antibody against Hepatitis E virus infection with undetectable viral load, iii) HIV infected individuals, and iv) solid organ transplant recipients. Furthermore, we will analyze three animal populations: i) suburban rodents, ii) domestic rodents, iii) wild carnivores. Viral sequences identified in both human and animal populations will be compared to evaluate the zoonotic origin of the infections.

Read the detailed description

To carry out the project a database will be created in electronic format, where the study team will integrate epidemiological, clinical and laboratory tests data of patients. Data will be anonymous and coded by a data manager.

Primary objective is to assess the prevalence of Ortho-C infection in patients with acute hepatitis of no identified origin

Secondary objectives are:

  1. To evaluate the prevalence and risk factors of Ortho-C infection in patients with solid organ transplant.
  2. To evaluate the prevalence and risk factors of Ortho-C infection in patients with HIV infection.
  3. To assess the presence of Ortho-C infection in patients with the presence of antibodies (IgM) against HEV and absence of HEV-RNA
  4. To evaluate the prevalence of infection by Ortho-C in wild and periurban rodents.
  5. To evaluate the prevalence of infection by Ortho-C in domestic rodents and mustelids.
  6. To evaluate the prevalence of infection by Ortho-C in wild carnivores
  7. To molecularly characterize and evaluate the degree of homology of Ortho-C viral sequences found in humans and animals
02

Conditions studied

  • Hepatitis
  • Liver Diseases
  • Acute Hepatitis
  • Chronic Hepatitis
  • Liver Disease Chronic

Keywords

  • Orthohepevirus C
  • Hepatitis
  • Liver Diseases
03

In context

Hepatitis A

2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.

This study's planned enrollment of 3,257 is above the median of 250 across 687 observational studies indexed under Hepatitis A.

Browse Hepatitis A studies →

Lead sponsor

Maimónides Biomedical Research Institute of Córdoba is the lead sponsor of 78 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Depending on the cohort. Please see "Group and Interventions" section to learn about the study population in each cohort.

Eligibility criteria

  1. HAOD cohort (Cohort of patients with acute hepatitis of unknown origin)
  • Patients older than 18 years with acute hepatitis of unknown origin (HAOD)

    1. OrthoC-Tx cohort (HEV Screening Cohort in Transplant Patients):
  • Kidney or liver transplant subjects

    1. Ortho-CoRIS Cohort (derived from the AIDS Research Network Cohort (CoRIS))
  • HIV-infected patients being monitored by the Spanish AIDS Research Network (RIS)

    1. TrazHE Cohort (Traceability cohort of Hepatitis E infections)
  • Patients with the presence of antibodies (IgM) against HEV and absence of HEV-RNA

    1. Ortho-C-Rodent Collection:
  • Wild and peri-urban rodents (rats) from different areas of Spain

    1. Ortho-C-Domestic Rodent Collection:
  • Domestic rodents and mustelids under follow-up in veterinary clinics of different Spanish municipalities.

    1. Ortho-C-Carnivore Collection:
  • Wild carnivores that eat rodents collected by the research team since 2020 in 4 autonomous communities (Extremadura, Andalusia, Murcia and Castilla la Mancha)
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
3,257 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • HAOD Cohort

    This cohort includes patients with acute hepatitis of unknown origin, meaning its origin could not be determined after screening of (at least) HAV, HAB, HAC, HAE, Epstein-Barr virus and cytomegalovirus. Patients will be recruited in 17 centres nationwide. The research group will receive a 1mL plasma / serum sample from each patient to study the presence of Ortho-C infection

  • OrthoC-Tx Cohort

    This cohort includes liver or kidney transplant patients under follow-up. The research group will receive a 1mL plasma / serum sample every year from each patient to study the presence of Ortho-C infection

  • Ortho-CoRIS Cohort

    This cohort includes VIH positive patients who are in follow-up by the Spanish Network of AIDS Research. The research group will receive a plasma / serum sample every year from each patient to study the presence of Ortho-C infection.

  • TrazHE Cohort

    This cohort includes patients whose clinical picture is compatible with HAE infection. The presence of Ortho-C infection will be studied in patients with positive IgM for HAE and absence of RNA-HAE.

  • Ortho-C-Rodent Cohort

    This cohort includes wild rats. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in wild rats (Ortho-C's main reservoir).

  • Ortho-C-Domestic Rodent Cohort

    This cohort includes domestic rats and mustelids. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in domestic rats and mustelids.

  • Ortho-C-Carnivore Cohort

    This cohort includes 236 wild carnivores that feed off rodents. Carnivores' cause of death is they were run over. Feces, liver and serum samples will be taken to study the transmission of Ortho-C.

06

What researchers measure

Primary outcomes

  1. Existence of Ortho-C infection

    The presence of Ortho-C infection is defined by: * HAOD, TrazHE, OrthoC-Tx and Ortho-CoRIS cohorts: presence of RNA-OrthoC in blood. * Ortho-C-Rodent and Ortho-C-Carnivore cohorts: presence of RNA-OrthoC in serum, feces and/or liver tissue * Ortho-C-Domestic-Rodent cohort: presence of RNA-OrthoC in feces.

    Time frame: Yearly, up to three years.

07

Study locations

10 sites
  • Hospital de Jerez de La Frontera
    Jerez De La Frontera, Cádiz, Spain
    • JUAN CARLOS ALADOS ARBOLEDAS · Contact
    • JUAN CARLOS ALADOS ARBOLEDAS · Principal investigator
  • Hospital de Puerto Real
    Puerto Real, Cádiz 11510, Spain
    • CAROLINA FREYRE CARRILLO · Contact
    • CAROLINA FREYRE CARRILLO · Principal investigator
  • Fundacion Instituto de Investigacion Sanitaria de Santiago de Compostela
    Santiago De Compostela, Galicia, Spain
    • ANTONIO AGUILERA GUIRAO · Contact
    • ANTONIO AGUILERA GUIRAO · Principal investigator
  • Instituto de Investigacion En Recursos Cinegeticos (Irec)
    Ciudad Real, Spain
    • JOSE FRANCISCO RUIZ FONS · Contact
    • JOSE FRANCISCO RUIZ FONS · Principal investigator
    • RAUL CUADRADO MATIAS · Sub investigator
  • Facultad de Veterinaria de Cordoba
    Córdoba, 14004, Spain
    • DAVID CANO TERRIZA · Contact
    • DAVID CANO TERRIZA · Principal investigator
  • Fundacion Investigacion Biomedica de Cordoba (Fibico)
    Córdoba, 14004, Spain
    • ANTONIO RIVERO ROMAN · Contact
    • ANGELA CAMACHO ESPEJO · Sub investigator
    • ANTONIO RIVERO ROMAN · Principal investigator
    • ISABEL MARIA MACHUCA SANCHEZ · Sub investigator
    • ANA BELEN PEREZ JIMENEZ · Sub investigator
  • Instituto Maimonides de Investigacion Biomedica de Cordoba (Imibic)
    Córdoba, 14004, Spain
  • Hospital Universitario San Cecilio
    Granada, Spain
    • ANA FUENTES LOPEZ · Contact
    • ANA FUENTES LOPEZ · Principal investigator
  • Clinica Universidad de Navarra
    Madrid, Spain
    • GABRIEL REINA GONZALEZ · Contact
    • GABRIEL REINA GONZALEZ · Principal investigator
  • Complejo Hospitalario de Especialidades Virgen de La Victoria
    Málaga, Spain
    • ISABEL VICIANA RAMOS · Contact
    • ISABEL VICIANA RAMOS · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Sharing the results of this study after they are made public.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05062967
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Responsible party
Sponsor
First posted
Sep 30, 2021
Start date
Jan 1, 2022 (estimated)
Primary completion
Oct 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Sep 30, 2021

Study contacts

ANTONIO RIVERO ROMÁN
Contact
ariveror@gmail.com
957012421
ANTONIO RIVERO ROMÁN
principal investigator · Hospital Universitario Reina Sofía

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion